Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | GPX4 | P36969 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | YAP1 | P46937 | 1/20 | 0.41 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11844730 | 0.87 | — | — | |
| SCHEMBL8978116 | 0.87 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2HTTPOLBTDP1 | |
| SCHEMBL9279972 | 0.87 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2HTTPOLBTDP1 | |
| SCHEMBL23194425 | 0.81 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2HTTPOLBLMNA | |
| SCHEMBL10466478 | 0.81 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2HTTPOLBLMNA | |
| SCHEMBL318820 | 0.81 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2HTTPOLBCYP1A2 | |
| Hydrochloric Acid SCHEMBL6031483 | 0.79 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2HTTPOLBCYP1A2 | |
| SCHEMBL37407 | 0.79 | — | — | |
| SCHEMBL860793 | 0.79 | CYP1A2 (0.77) | ALDH1A1SMN1; SMN2POLBCYP1A2TDP1 | |
| SCHEMBL14407779 | 0.79 | CYP1A2 (0.77) | ALDH1A1SMN1; SMN2POLBCYP1A2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368608-A1 | SELECTIVE HDAC6 INHIBITOR | ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2025-12-04 | — | — | US | disclosed |
| WO-2022129256-A1 | SELECTIVE HDAC6 INHIBITOR | ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2022-06-23 | — | — | WO | disclosed |
| US-11332459-B2 | Benzimidazole derivatives and their uses | TEIJIN PHARMA LIMITED (JP) | 2022-05-17 | — | — | US | disclosed |
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2020-10-01 | — | — | US | disclosed |
| US-20060281789-A1 | Protein kinase inhibitors | KYOWA HAKKO KOGYO CO., LTD (JP) | 2006-12-14 | — | — | US | disclosed |
| EP-1650194-A1 | PROTEIN KINASE INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368608-A1 | SELECTIVE HDAC6 INHIBITOR | HDAC6, HDAC3, HDAC1 | ALDH1A1 3394/4885SMN1; SMN2 671/4885HTT 293/4885 |
| US-20060281789-A1 | Protein kinase inhibitors | MAP3K20, MAP3K1, MAP3K19 | ALDH1A1 2999/4885SMN1; SMN2 4204/4885HTT 4154/4885 |
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | TRPC6, TRPV6, TRPM6 | ALDH1A1 1564/4885SMN1; SMN2 3653/4885HTT 2535/4885 |
| US-11332459-B2 | Benzimidazole derivatives and their uses | TRPC6, TRPV6, TRPM6 | ALDH1A1 1564/4885SMN1; SMN2 3653/4885HTT 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.